Navigation Links
Neuradiab in Medical News

Bradmer provides Phase III Neuradiab trial update and guidance

TSX: BMR TORONTO, Oct. 15 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it held a pre-Phase III meeting with the U.S. Food and Drug ...

Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid

...equally. We continue to evaluate opportunities to maximize the value of the neuradiab asset, however a substantial portion of the existing cash on hand will be u...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer announces 2009 first quarter operational and financial results

...luate strategic options. "Despite our pride in the progress made bringing neuradiab from a single-site Phase II program to a multicenter Phase III registration...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer announces 2008 fourth quarter and fiscal year operational and financial results

...tinuing to evaluate strategic options. "We have successfully transitioned neuradiab from a Phase II compound with compelling results at a single site to a cGMP...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer implements cash conservation plan

...tends to maintain the ability to pursue business development strategies for neuradiab and is continuing to explore opportunities that would permit further develo...lment in a Phase III multi-center clinical trial of the licensed treatment. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer provides clinical trial update and announces evaluation of strategic alternatives

...l patient survival from 53 to 64 weeks. About neuradiab neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...

Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference

... form of brain cancer, glioblastoma multiforme. Bradmer has initiated enrollment in a Phase III multi-center clinical trial of the licensed treatment. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency. Bradmer Pharmaceuticals ...

Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting

...ponse of newly diagnosed GBM patients treated with neuradiab as an adjunct to the current standard of care, con...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy, consistin...NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...

Bradmer announces 2008 third quarter operational and financial results

...ART Trial and successfully dosed patients with neuradiab at multiple sites; - Announced new data from the...llow a two week extension of the shelf life of neuradiab beyond the current six-day specification; and ...y to provide a definitive answer on the benefit of neuradiab in the newly diagnosed GBM population." The Phas...

Bradmer to present at Rodman & Renshaw Healthcare Conference

...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy, consistin...dy identifier NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...
Neuradiab in Medical Technology

Molecular Target of Bradmer's Neuradiab Further Validated by Independent Findings

TSX: BMR TORONTO, July 10, 2007 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that new research published by an independent team in Basel, Switzerland validates tenascin as ...

Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials

...ical trial, termed the GLASS-ART Trial, evaluating neuradiab as an adjunct therapy to the current standard of c...e control arm. "These PFS data from the Phase II neuradiab trials exceed the results achieved in any other cl...nt of median overall survival, the opportunity for neuradiab to demonstrate a patient benefit via the parameter...
Neuradiab in Biological Technology

Bradmer sponsors physician panel to raise awareness of brain cancer treatments

...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy for patien...dy identifier NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...
Other Tags
(Date:3/1/2015)... Orion, Metamora, Michigan (PRWEB) March 01, 2015 ... is approved to treat Overactive Bladder (OAB) symptoms, such as ... in adults when another type of medication (anticholinergic) does not ... a different treatment option that takes another approach to targeting ... , BOTOX® works on the nerves and bladder muscle, blocking ...
(Date:3/1/2015)... Ticket Down is a reputable source for ... Soldier Field. Deadheads have been anxiously anticipating this blockbuster ... Dead was formed 50 years ago back in the 60s ... until the untimely death of Jerry Garcia in 1995. ... blues, reggae, rock, bluegrass, folk, space rock and country to ...
(Date:3/1/2015)... Aliso Viejo, California (PRWEB) March 01, 2015 ... have announced a new transition pack for ... users to add accordion style transitions to any FCPX ... Studios. “We’ve given our users the tools needed to ... FCPX media.” , The user gets many different controls ...
(Date:2/28/2015)... In a recent episode of ... Game Change Athlete Development Services and Consultancy talks ... of athlete development and player engagement during and after ... that athletes face and how off-field activities are a ... became involved in athlete development issues while in graduate ...
(Date:2/28/2015)... Morristown, NJ (PRWEB) February 28, 2015 ... Month—is a good time to remind ourselves and ... be ignored, say Atlantic NeuroSurgical Specialists (ANS). , ... (TBI), which account for 75% of TBIs. There ... word concussion may sound benign, but it is ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3
(Date:2/19/2015)... 2015 Research and Markets ( ... "Military Electro-Optical / Infrared Systems Market by ... - Forecast to 2020" report to their ... market is expected to reach $16.35 billion by ... This report segments the military electro-optical/infrared systems ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62/113114 for DISTRIBUTED METHOD AND ... The patent further establishes NXT-ID,s position in the ... property portfolio the ability for multiple devices to collaborate ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, North Carolina , ... in sein 35. Jahr als spezialisiertes Logistikunternehmen ... seine Position als einzige klinische Logistikfirma (Clinical ... soll. Die Kernbotschaft der neuen Kampagne lautet ... Protokollen und Lieferungen. Foto: ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
Other Contents